Pepcid AC first-year retail sales top $200 mil., exceeding record set by Aleve -- J&J/Merck.
This article was originally published in The Tan Sheet
Executive Summary
PEPCID AC FIRST-YEAR RETAIL SALES TOP $200 MIL., Johnson & Johnson/Merck said in an April 18 release. The company began shipping the product to retailers in May 1995 after FDA's approval of the Rx-to-OTC switch on April 28, 1995. Now the third largest selling OTC in the U.S. after Tylenol and Advil, Pepcid AC is outpacing the previous first-year sales record for a switch product, Procter-Syntex' Aleve, by more than $90 mil., J&J/Merck said.